Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: Correlation with the week of onset and the severity

Prenatal Diagnosis

Volumn 28, Issue 8, 2008, Pages 704-709

  Kang, Jin Hee ^a   Farina, Antonio ^b   Park, Ji Hyeon ^a   Kim, Sung Han ^c   Kim, Ji Yeon ^a   Rizzo, Nicola ^b   Elmakky, Amira ^b   Jun, Hye Sun ^a   Hahn, Won Bo ^a   Cha, Dong Hyun ^a  

^a CHA University   (South Korea)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Digital Genomics   (South Korea)

Author keywords

Biochemical markers; Down syndrome; Inhibin A; Preeclampsia; Prenatal diagnosis

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL; INHIBIN A; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PREECLAMPSIA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCREENING TEST; SECOND TRIMESTER PREGNANCY;

ADULT; BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 49949105671     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1997     Document Type: Article

References (35)

1. Aquilina J, Maplethorpe R, Ellis P, Harrington K. 2000. Correlation between second trimester maternal serum inhibin-A and human chorionic gonadotrophin for the prediction of preeclampsia. Placenta 21: 487-492.
2. Baumann MU, Bersinger NA, Surbek DV. 2007. Serum markers for predicting pre-eclampsia. Mol Aspects Med 28: 227-244.
3. Bersinger NA, Smarason AK, Muttukrishna S, Groome NP, Redman CW. 2003. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Pregnancy 22: 45-55.
4. Birdsall M, Ledger W, Groome N, Abdalla H, Muttukrishna S. 1997. Inhibin A and activin A in the first trimester of human pregnancy. J Clin Endocrinol Metab 82: 1557-1560.
5. Clemmons DR. 1998. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 140: 19-24.
6. Cuckle H, Sehmi I, Jones R. 1998. Maternal serum inhibin A can predict pre-eclampsia. Br J Obstet Gynecol 105: 1101-1103.
7. Dugoff L. 2002. Ultrasound diagnosis of structural abnormalities in the first trimester. Prenat Diagn 22: 316-320.
8. Dugoff L, Hobbins JC, Malone FD, et al. 2004. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonodotropin concentrations and nuchal translucency are associated with obstetric complication: A population-based screening study (The FASTER Trial). Am J Obstet Gynecol 191: 1446-1451.
9. Dugoff L, Hobbins JC, Malone FD, et al. 2005. Quad screen as predictor of adverse pregnancy outcome. Obstet Gynecol 106: 260-267.
10. Irwin JC, Suen LF, Martina NA, Mark SP, Giudice LC. 1999. Role of the IGF system in trophoblast invasion and pre-eclampsia. Hum Reprod 14: S90-S96.
11. King I, Williams M, Srensen T, Luthy D. 1998. Inhibin A and activin A levels in the second trimester as predictors of pre-eclmpsia. Am J Obstet Gynecol 178: S115.
12. Lawrence JB, Oxvig C, Overgaard MT, et al. 1999. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 96: 3149-3153.
13. Leung TN. Chung TK, Madsen G, et al. 2000. Analysis of mid-trimester corticotrophin-releasing hormone and alpha-fetoprotein concentrations for predicting preeclampsia. Hum Reprod 15: 1813-1818.
14. Malone FD, Canick JA, Ball RH, et al. 2005. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 353: 2001-2011.
15. McCluggage WG, Ashe P, McBride H, Maxwell P, Sloan JM. 1998. Localization of the cellular expression of inhibin in trophoblastic tissue. Histopalhology 32: 252-256.
16. Muttukrishna S, George L, Fowler PA, Groome NP, Knight PG. 1995. Measurement of serum concentration of inhibin-A (alpha-beta A dimmer) during human pregnancy. Clin Endocrinol 42: 391-397.
17. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger W. 1997. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 349: 1285-1288.
18. Muttukrishna S, North RA, Morris J, et al. 2000. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod 15: 1640-1645.
19. Ong CYT, Liao AW, Spencer K, Munim S, Nicolaides KP. 2000. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 107: 1265-1270.
20. Qu J, Thomas K. 1995. Inhibin and activin production in human placenta. Endocr Rev 16: 485-507.
21. Raty R, Koskinen P, Alanen A, Irjala K, Matinlauri I, Ekblad U. 1999. Prediction of pre-eclampsia with maternal mid-trimester total rennin, inhibin A, AFP and free beta-hCG levels. Prenat Diagn 19(2): 122-127.
22. Redman CW, Sargent IL. 2005. Latest advances in understanding preeclampsia. Science 308: 1592-1594.
23. Shenhav S, Gemer O, Sassoon E, Volodarsky M, Peled R, Segal S. 2002. Mid-trimester triple test levels in early and late onset severe pre-eclampsia. Prenat Diagn 22: 579-582.
24. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. 2002. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 87: 1762-1767.
25. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH. 2005. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 192: 1005-1021.
26. Spencer K. 1993. Screening for Down's syndrome, the role of intact hCG and free subunit measurement. Scand J Clin Lab Invest 216: 79-96.
27. Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA. 2000. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia? Am J Obstet Gynecol 182(3): 589-594.
28. Toop K, Klopper A. 1981. Concentration of pregnancy-associated plasma protein A (PAPP-A) in patients with pre-eclamptic toxaemia. Placenta Suppl 3: 167-173.
29. Troisi R, Potischman N, Roberts JM, et al. 2003. Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. Int J Epidemiol 32: 455-460.
30. Tsai MS, Lee FK, Cheng CC, Hwa KY, Cheong ML, She BQ. 2002. Association between fetal nuchal translucency thickness in first trimester and subsequent gestational hypertension and preeclampsia. Prenat Diagn 22: 747-751.
31. Wald NJ, Morris JK. 2001. Multiple marker second trimester serum screening for pre-eclampsia. J Med Screen 8: 65-68.
32. Wald NJ, Morris JK, Ibison J, Wu T, George LM. 2006. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. Prenat Diagn 26: 559-564.
33. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. 2003. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine, and Ultrasound Screening Study (SURUSS). J Med Screen 10: 56-104.
34. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. 1996. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 88(5): 816-822.
35. Yaron Y, Cherry M, Kramer RL, et al. 1999. Second-trimester maternal serum marker screening: maternal serum α-fetoprotein, β-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 181: 968-974.